title: Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
abstract: BACKGROUND
  Extramedullary pancreatic plasmacytoma treated with bortezomib is rarely reported.
  
  
  METHODS
  We admitted a 53-year-old woman with an asymptomatic mass above the left clavicle for over three months, then an asymptomatic swelling of the pancreas was found. A biopsy on the mass and a fine needle aspiration of the pancreas were performed. The diagnosis of extramedullary plasmacytoma (EMP) was made. The patient was initially treated with combination chemotherapy consisting of vincristine, doxorubicin and dexamethasone (VAD regimen). She progressed to painless jaundice during the chemotherapy. Then she was treated with bortezomib and hyper-dose dexamethasone. As a result, she had a near complete remission.
  
  
  RESULTS
  The data demonstrated that the diagnosis was EMP of the pancreas. The patient responded very well to bortezomib, while failing to respond to the traditional chemotherapy regimen of VAD.
  
  
  CONCLUSIONS
  EMP of the pancreas is rare. This case gives evidence for an excellent response of EMP of the pancreas to bortezomib.
authors.affiliation: Department of Hematology, Institute of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
authors.forename: Ju-Ying
authors.initials: JY
authors.lastname: Wei
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Tong
authors.forename: Wei-Fang
authors.initials: WF
authors.lastname: Zhu
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Feng-Juan
authors.initials: FJ
authors.lastname: Zhang
authors.forename: Wen-Juan
authors.initials: WJ
authors.lastname: Yu
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003561:Cytarabine / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010954:Plasmacytoma / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000008:administration & dosage*; D019233:Retreatment; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001897:Boronic Acids; D011719:Pyrazines; D003561:Cytarabine; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone